ClinicalTrials.gg
RecruitingNCT06223828CR-AZI KidsUpdated Aug 11, 2026

Azithromycin for Critical Asthma - Pediatrics

A Phase 2/3 interventional study of Azithromycin in Pediatric Asthma and Critical Illness, sponsored by Johns Hopkins All Children's Hospital. Recruiting at 1 site in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-11.

Sponsored by Johns Hopkins All Children's Hospital · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
3 Years to 17 Years
Sex
All
01

Study summary

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Read the detailed description

Azithromycin (AZI), a macrolide antibiotic, has been applied for adult and pediatric respiratory pathology to alter immune system response.1 For pediatric critical asthma (CA), a term used to describe a critically ill child hospitalized with an asthma exacerbation requiring an intensive care unit (PICU) hospitalization, the investigator's prior research has revealed 1 in 10 will receive AZI.2 Yet, the application of AZI in this setting is poorly studied nor is clear if, and to what degree AZI alters the immune response in conjunction with systemic corticosteroids traditionally applied in CA.

In this proposal, the investigators aim to characterize a respiratory epithelial inflammatory biomarker, periostin, among children with CA with and without exposure to AZI. The investigators hypothesize children receiving AZI will have lower periostin levels. As a secondary analysis, the investigators will describe the rates of adverse events related to AZI (previously not done) and explore differences in clinical and physiologic CA efficacy markers.

02

Conditions studied

  • Pediatric Asthma
  • Critical Illness

Browse trials for

03

In context

Critical Illness

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's planned enrollment of 100 is above the median of 90 across 930 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Johns Hopkins All Children's Hospital is the lead sponsor of 25 studies on the registry; 6 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 3-17 years
  • Admission to the PICU
  • Primary diagnosis of critical asthma
  • Prescription for continuous inhaled beta-agonist therapy and/or intravenous (IV) beta-agonist therapy
  • Prescription for intravenous systemic

Exclusion criteria

Exclusion criteria

  • Critical Congenital Heart Disease Unrepaired
  • Tracheostomy Dependence at Admission
  • Ongoing Exposure to Azithromycin or Macrolide Antibiotics for any indication
  • Past Medical History of Prolonged Syndrome or Arrhythmias
  • Concomitant respiratory pathology including Acute Chest Syndrome, Interstitial Lung Disease, Cystic Fibrosis, and pulmonary hypertension
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Azithromycin Intervention

    Participants in this arm will receive Azithromycin 10mg/kg/dose (max dose 500mg) once daily for 3 days.

    Drug: Azithromycin

  • No intervention
    Standard Care

    Participants will receive standard care without Azithromycin.

Interventions

  • 10mg/kg/dose (max dose 500mg) once daily for 3 days

    Also known as: Zithromax

06

What researchers measure

Primary outcomes

  1. Plasma Periostin Levels and Degree of Change (e.g., Slope) - Primary Physiologic Efficacy Endpoint

    ng/dL

    Time frame: 24 hours, 48 hours, and 72-hours following enrollment

  2. Drug-related adverse event rate (Primary Safety Endpoint)

    cumulative incidence rate

    Time frame: During hospitalization, approximately 3 days

Secondary outcomes

  1. Length of Stay (Secondary Clinical Efficacy Endpoint)

    Measured in Days, from Hospitalization in ICU through Discharge from ICU

    Time frame: During hospitalization, approximately 3 days

  2. Duration of continuous albuterol (Secondary Clinical Efficacy Endpoint)

    Measured in Hours from ICU hospitalization through discharge

    Time frame: During hospitalization, approximately 3 days

  3. Composite use of adjunct asthma treatments (Secondary Clinical Efficacy Endpoint)

    Cumulative Frequency of Exposure, from ICU Hospitalization through ICU discharge

    Time frame: During hospitalization, approximately 3 days

  4. Transcutaneous carbon dioxide levels (Secondary physiologic efficacy Endpoint)

    Measured in mmHg of Carbon Dioxide, peak values measured daily at each study visit

    Time frame: Enrollment, Day 1, Day 2, Day 3, at ICU Discharge

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — No plan to share with other researchers.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2026, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2024
First posted
Jan 25, 2024
StartActual
Apr 2, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Aug 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06223828
Lead sponsor
Johns Hopkins All Children's Hospital
Responsible party
Sponsor
First posted
Jan 25, 2024
Start date
Apr 2, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Aug 11, 2026

Study contacts

Anthony A Sochet, MD
Contact
Sochet@jhmi.edu
727-487-3711
Alexa R Roberts, MD
Contact
arober77@jhmi.edu
602-526-4397
Anthony A Sochet, MD
principal investigator · Johns Hopkins All Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Azithromycin

Start the discussion